HomeHome
ProductsProducts
Bioactive CompoundsBioactive Compounds
AutophagyAutophagy
Autophagy ModulatorsAutophagy Modulators
N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamideCAS 802539-81-7

N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

CAS No.	802539-81-7
MDL No.	MFCD17169990
MF	C₂₅H₃₂N₈O
MW	460.60
InChI Key	RXZMYLDMFYNEIM-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT→

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	802539-81-7
Product Name	N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

Biological Targets

CDK1·CDK2·CDK4·NTRK1

Associated Conditions

Thymic Carcinoma·Thymoma·neoplasm·hepatocellular carcinoma

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

Journal of medicinal chemistry • Vol. 61, Issue 20 • 2018

PMID: 30234987 DOI: 10.1021/acs.jmedchem.8b00049

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.

Biochemical pharmacology • Vol. 84, Issue 5 • 2012

PMID: 22704958 DOI: 10.1016/j.bcp.2012.06.004

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

Molecular cancer therapeutics • Vol. 9, Issue 8 • 2010

PMID: 20682657 DOI: 10.1158/1535-7163.MCT-10-0190

Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.

Molecular cancer therapeutics • Vol. 9, Issue 3 • 2010

PMID: 20197397 DOI: 10.1158/1535-7163.MCT-09-0726

Similar Products

Onvansertib
CAS No.1034616-18-6
NMS-P715
CAS No.1202055-32-0
2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[(2S)-5-[[(2S)-2-[4-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]propanoyl]amino]phenyl]-2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]carbamoyloxy]ethyl]amino]-2-[[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]acetyl]amino]-5-oxopentanoyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetic acid
CAS No.2845165-06-0
LNK4-S
CAS No.2845165-06-0
[4-[[(2S)-6-amino-2-[[(2S)-2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]phenyl]methyl [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] carbonate
CAS No.1036969-20-6
Vinorelbine
CAS No.71486-22-1

Products
- CDMO Compounds
- API & Candidates
Services
CDMO & Manufacturing
Custom Synthesis
Process Development
Lab To Pilot
Commercialization
Generic APIs
CRO
Preclinical
Pharmacology & Efficacy
DMPK & Bioanalysis
Toxicology & Safety
Disease Models
Technologies
High-Potent
Chiral Synthesis
Cloud Synthesis
Fermentation
Flow Chemistry
Biocatalysis
Support
Regulatory Support
Supply Chain Solutions
About
Perspectives
Contact

HomeHome
ProductsProducts
Bioactive CompoundsBioactive Compounds
AutophagyAutophagy
Autophagy ModulatorsAutophagy Modulators
N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamideCAS 802539-81-7

N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

CAS No.	802539-81-7
MDL No.	MFCD17169990
MF	C₂₅H₃₂N₈O
MW	460.60
InChI Key	RXZMYLDMFYNEIM-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT→

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	802539-81-7
Product Name	N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

Biological Targets

CDK1·CDK2·CDK4·NTRK1

Associated Conditions

Thymic Carcinoma·Thymoma·neoplasm·hepatocellular carcinoma

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

Journal of medicinal chemistry • Vol. 61, Issue 20 • 2018

PMID: 30234987 DOI: 10.1021/acs.jmedchem.8b00049

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.

Biochemical pharmacology • Vol. 84, Issue 5 • 2012

PMID: 22704958 DOI: 10.1016/j.bcp.2012.06.004

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

Molecular cancer therapeutics • Vol. 9, Issue 8 • 2010

PMID: 20682657 DOI: 10.1158/1535-7163.MCT-10-0190

Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.

Molecular cancer therapeutics • Vol. 9, Issue 3 • 2010

PMID: 20197397 DOI: 10.1158/1535-7163.MCT-09-0726

Similar Products

Onvansertib
CAS No.1034616-18-6
NMS-P715
CAS No.1202055-32-0
2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[(2S)-5-[[(2S)-2-[4-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]propanoyl]amino]phenyl]-2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]carbamoyloxy]ethyl]amino]-2-[[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]acetyl]amino]-5-oxopentanoyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetic acid
CAS No.2845165-06-0
LNK4-S
CAS No.2845165-06-0
[4-[[(2S)-6-amino-2-[[(2S)-2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]phenyl]methyl [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] carbonate
CAS No.1036969-20-6
Vinorelbine
CAS No.71486-22-1

Your Partner for
Complex Chemistry

About Us
Perspectives
Products
Contact

Preclinical Development
Technologies
Custom Synthesis

Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT

Westerstraat 10, 3016 DH, Rotterdam, The Netherlands

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|

N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.

Similar Products

Onvansertib

NMS-P715

LNK4-S

Vinorelbine

N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.

Similar Products

Onvansertib

NMS-P715

LNK4-S

Vinorelbine

Documentation